Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

fdaoutsideweb

FDA warning slams St Jude’s “inadequate response” to device failures

April 13, 2017 Medical Communications, Sales and Marketing FDA, st jude medical

St Jude Medical has been hit with a warning letter from the FDA over the medical device manufacturer’s failure to …
News
fdaoutsideweb

FDA approves first and only tardive dyskinesia treatment

April 12, 2017 Research and Development, Sales and Marketing FDA, Neurocrine Biosciences, tardive dyskinesia

US patients suffering with tardive dyskinesia (TD) will see access to the first approved treatment in the country with the …
News
raymond_barlow

e-Therapeutics installs new CEO in position

April 11, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing e-Therapeutics

e-Therapeutics, a drug discovery company, announced that Dr. Raymond Barlow assumed the position of CEO at the beginning of April. …
Appointment
shutterstock_36423250

Trials and Tribulations: The impact of new clinical trial regulation in Europe

April 11, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, UK, brexit, clinical trials, regulations

The clinical trial is the fulcrum on which drug development and treatment hinges. Even with the advent of new technologies …
Feature
shigella

Hilleman labs partners with Indian Government for shigella vaccine

April 11, 2017 Manufacturing and Production, Sales and Marketing NICED, hilleman, shigella

India’s Hilleman Laboratories and the National Institute of Cholera and Enteric Diseases (NICED) are set to develop and market a …
News
embotrap

J&J acquires Neuravi to bolster neuro business

April 11, 2017 Manufacturing and Production, Sales and Marketing Johnson & Johnson, Neuravi

Johnson & Johnson’s neurosurgery and neurovascular unit, Codman Neuro, has made the move to acquire Galway-based company, Neuravi. The exact …
News
janssen_latest_logo_on_sign_closer

Scotland recommends Janssen’s Imbruvica for leukaemia

April 11, 2017 Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia

Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …
News
opdivo_1_1

NICE turns down BMS’ Opdivo for head and neck cancer

April 11, 2017 Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo

Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …
News

Bioverativ installs new EVP of R&D

April 10, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing bioverativ

Bioverativ, a biotech company that develops therapies for rare blood disorders, announced the appointment of Tim Harris as Executive Vice …
Appointment
gilead-sciences

FDA approves first two antiviral hep C drugs for paediatric patients

April 10, 2017 Sales and Marketing FDA, harvoni, hepatitis C, sovaldi

The FDA has given the go-ahead for two hepatitis C treatments for use in young and adolescent patients: Sovaldi (sofosbuvir) …
News
human-ear-1462020301zmm

Virus fixes DNA mutations for possible hearing loss therapy

April 10, 2017 Research and Development, Sales and Marketing Ear, deafblindness, hearing loss, inner hair

Researchers at the Medical School at Harvard and MedUni Vienna’s Department of Ear, Nose and Throat Diseases have managed to …
News
actelion

EMA green lights Actelion’s drug after patient deaths scare

April 10, 2017 Sales and Marketing Actelion, Johnson & Johnson, Uptravi

The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …
News
roche_dark_0

Roche’s lung cancer drug beats Pfizer rival in study

April 10, 2017 Research and Development, Sales and Marketing Alecensa, Roche

Roche has announced that its drug Alecensa (alectinib) succeeded in meeting its primary endpoint in a Phase 3 trial assessing …
News

Fresenius confirms takeover talks with Akorn

April 10, 2017 Sales and Marketing Akorn, Fresenius

Fresenius, Europe’s largest publicly traded healthcare provider, has engaged in discussions with Akorn, a pharmaceutical generics drugmaker, with a view …
News
novartis_outside_1

Novartis takes on dry-eye market with drug in-licensing move

April 7, 2017 Medical Communications, Sales and Marketing Lubris, Novartis, dry eye

Novartis has announced that its eyecare-focused division Alcon has in-licensed dry-eye drug ECF843 from US firm Lubris for ophthalmic indications …
News
The Gateway to Local Adoption Series

Latest content

How will biomarker-led diagnostics reshape respiratory medicine?

October 11, 2026

Five Facts about COPD

October 11, 2026

“That gap between innovation and delivery was what stood out to me most”

October 11, 2026

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster

October 11, 2026

Fortysomethings’ non-attendance at NHS Health Checks raises concerns, says study

October 11, 2026